Cargando…
The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
OBJECTIVES: This meta-analysis of randomized controlled trials (RCTs) investigated the usefulness of mesenchymal stromal cells (MSCs) to treat patients with COVID-19. Methods: PubMed, Embase, Ovid MEDLINE, the Cochrane Library, and Clinicaltrials.gov were searched for RCTs published before November...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259515/ https://www.ncbi.nlm.nih.gov/pubmed/35849852 http://dx.doi.org/10.1016/j.jiph.2022.07.001 |
_version_ | 1784741800409300992 |
---|---|
author | Chen, Ching-Yi Chen, Wang-Chun Hsu, Chi-Kuei Chao, Chien-Ming Lai, Chih-Cheng |
author_facet | Chen, Ching-Yi Chen, Wang-Chun Hsu, Chi-Kuei Chao, Chien-Ming Lai, Chih-Cheng |
author_sort | Chen, Ching-Yi |
collection | PubMed |
description | OBJECTIVES: This meta-analysis of randomized controlled trials (RCTs) investigated the usefulness of mesenchymal stromal cells (MSCs) to treat patients with COVID-19. Methods: PubMed, Embase, Ovid MEDLINE, the Cochrane Library, and Clinicaltrials.gov were searched for RCTs published before November 7, 2021. Only RCTs that compared the clinical efficacy and safety of MSCs with other alternative treatments or placebos in the treatment of patients with COVID-19 were included. RESULTS: Six RCTs were included, in which the MSC and control groups consisted of 158 and 135 patients, respectively. The patients who received MSCs had a significantly lower 28-day mortality rate (7.6% vs 21.5%; OR, 0.18; 95% CI, 0.06–0.52; I(2) = 0%) and significantly higher clinical improvement rate (OR, 6.05; 95% CI, 2.31–15.83; I(2) = 0%) than the controls. The patients who received MSCs were associated with a similar risk of adverse events (AEs) and serious AEs to the control group (AEs: OR, 33; 95% CI, 0.09–1.18; I(2) = 59%; serious AEs: OR, 0.30; 95% CI, 0.02–4.41; I(2) = 53%). CONCLUSIONS: MSC treatment may help to improve the clinical outcomes of patients with COVID-19. In addition, MSC treatment appears to be a safe therapeutic option for patients with COVID-19. |
format | Online Article Text |
id | pubmed-9259515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92595152022-07-07 The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials Chen, Ching-Yi Chen, Wang-Chun Hsu, Chi-Kuei Chao, Chien-Ming Lai, Chih-Cheng J Infect Public Health Original Article OBJECTIVES: This meta-analysis of randomized controlled trials (RCTs) investigated the usefulness of mesenchymal stromal cells (MSCs) to treat patients with COVID-19. Methods: PubMed, Embase, Ovid MEDLINE, the Cochrane Library, and Clinicaltrials.gov were searched for RCTs published before November 7, 2021. Only RCTs that compared the clinical efficacy and safety of MSCs with other alternative treatments or placebos in the treatment of patients with COVID-19 were included. RESULTS: Six RCTs were included, in which the MSC and control groups consisted of 158 and 135 patients, respectively. The patients who received MSCs had a significantly lower 28-day mortality rate (7.6% vs 21.5%; OR, 0.18; 95% CI, 0.06–0.52; I(2) = 0%) and significantly higher clinical improvement rate (OR, 6.05; 95% CI, 2.31–15.83; I(2) = 0%) than the controls. The patients who received MSCs were associated with a similar risk of adverse events (AEs) and serious AEs to the control group (AEs: OR, 33; 95% CI, 0.09–1.18; I(2) = 59%; serious AEs: OR, 0.30; 95% CI, 0.02–4.41; I(2) = 53%). CONCLUSIONS: MSC treatment may help to improve the clinical outcomes of patients with COVID-19. In addition, MSC treatment appears to be a safe therapeutic option for patients with COVID-19. The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022-08 2022-07-07 /pmc/articles/PMC9259515/ /pubmed/35849852 http://dx.doi.org/10.1016/j.jiph.2022.07.001 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Chen, Ching-Yi Chen, Wang-Chun Hsu, Chi-Kuei Chao, Chien-Ming Lai, Chih-Cheng The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
title | The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
title_full | The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
title_fullStr | The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
title_full_unstemmed | The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
title_short | The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
title_sort | clinical efficacy and safety of mesenchymal stromal cells for patients with covid-19: a systematic review and meta-analysis of randomized controlled trials |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259515/ https://www.ncbi.nlm.nih.gov/pubmed/35849852 http://dx.doi.org/10.1016/j.jiph.2022.07.001 |
work_keys_str_mv | AT chenchingyi theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chenwangchun theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT hsuchikuei theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chaochienming theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT laichihcheng theclinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chenchingyi clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chenwangchun clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT hsuchikuei clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT chaochienming clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT laichihcheng clinicalefficacyandsafetyofmesenchymalstromalcellsforpatientswithcovid19asystematicreviewandmetaanalysisofrandomizedcontrolledtrials |